The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases

Introduction: The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international disease registry designed to provide insights into the clinical characteristics of patients with Tuberous Sclerosis Complex (TSC). The aims of this study were to identify issues that arose during...

Full description

Bibliographic Details
Main Authors: Ruben Marques, Elena Belousova, Mirjana P. Benedik, Tom Carter, Vincent Cottin, Paolo Curatolo, Maria Dahlin, Lisa D'Amato, Guillaume Beaure d'Augères, Petrus J. de Vries, José C. Ferreira, Martha Feucht, Carla Fladrowski, Christoph Hertzberg, Anna C. Jansen, Sergiusz Jozwiak, John C. Kingswood, John A. Lawson, Alfons Macaya, Finbar O'Callaghan, Jiong Qin, Valentin Sander, Matthias Sauter, Seema Shah, Yukitoshi Takahashi, Renaud Touraine, Sotiris Youroukos, Bernard Zonnenberg, Rima Nabbout
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-11-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2019.01182/full
id doaj-acb3460301534cc9a945482e7e3a4221
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ruben Marques
Ruben Marques
Elena Belousova
Mirjana P. Benedik
Tom Carter
Vincent Cottin
Paolo Curatolo
Maria Dahlin
Lisa D'Amato
Guillaume Beaure d'Augères
Petrus J. de Vries
José C. Ferreira
Martha Feucht
Carla Fladrowski
Carla Fladrowski
Christoph Hertzberg
Anna C. Jansen
Sergiusz Jozwiak
Sergiusz Jozwiak
John C. Kingswood
John A. Lawson
Alfons Macaya
Finbar O'Callaghan
Jiong Qin
Valentin Sander
Matthias Sauter
Seema Shah
Yukitoshi Takahashi
Renaud Touraine
Sotiris Youroukos
Bernard Zonnenberg
Rima Nabbout
spellingShingle Ruben Marques
Ruben Marques
Elena Belousova
Mirjana P. Benedik
Tom Carter
Vincent Cottin
Paolo Curatolo
Maria Dahlin
Lisa D'Amato
Guillaume Beaure d'Augères
Petrus J. de Vries
José C. Ferreira
Martha Feucht
Carla Fladrowski
Carla Fladrowski
Christoph Hertzberg
Anna C. Jansen
Sergiusz Jozwiak
Sergiusz Jozwiak
John C. Kingswood
John A. Lawson
Alfons Macaya
Finbar O'Callaghan
Jiong Qin
Valentin Sander
Matthias Sauter
Seema Shah
Yukitoshi Takahashi
Renaud Touraine
Sotiris Youroukos
Bernard Zonnenberg
Rima Nabbout
The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
Frontiers in Neurology
lessons
issues
strengths
weaknesses
TOSCA
registry
author_facet Ruben Marques
Ruben Marques
Elena Belousova
Mirjana P. Benedik
Tom Carter
Vincent Cottin
Paolo Curatolo
Maria Dahlin
Lisa D'Amato
Guillaume Beaure d'Augères
Petrus J. de Vries
José C. Ferreira
Martha Feucht
Carla Fladrowski
Carla Fladrowski
Christoph Hertzberg
Anna C. Jansen
Sergiusz Jozwiak
Sergiusz Jozwiak
John C. Kingswood
John A. Lawson
Alfons Macaya
Finbar O'Callaghan
Jiong Qin
Valentin Sander
Matthias Sauter
Seema Shah
Yukitoshi Takahashi
Renaud Touraine
Sotiris Youroukos
Bernard Zonnenberg
Rima Nabbout
author_sort Ruben Marques
title The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
title_short The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
title_full The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
title_fullStr The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
title_full_unstemmed The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex Diseases
title_sort tosca registry for tuberous sclerosis—lessons learnt for future registry development in rare and complex diseases
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2019-11-01
description Introduction: The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international disease registry designed to provide insights into the clinical characteristics of patients with Tuberous Sclerosis Complex (TSC). The aims of this study were to identify issues that arose during the design, execution, and publication phases of TOSCA, and to reflect on lessons learnt that may guide future registries in rare and complex diseases.Methods: A questionnaire was designed to identify the strengths, weaknesses, and issues that arose at any stage of development and implementation of the TOSCA registry. The questionnaire contained 225 questions distributed in 7 sections (identification of issues during registry planning, during the operation of the registry, during data analysis, during the publication of the results, other issues, assessment of lessons learnt, and additional comments), and was sent by e-mail to 511 people involved in the registry, including 28 members of the Scientific Advisory Board (SAB), 162 principal investigators (PIs), and 321 employees of the sponsor belonging to the medical department or that were clinical research associate (CRA). Questionnaires received within the 2 months from the initial mailing were included in the analysis.Results: A total of 53 (10.4%) questionnaires were received (64.3% for SAB members, 12.3% for PIs and 4.7% for employees of the sponsor), and the overall completeness rate for closed questions was 87.6%. The most common issues identified were the limited duration of the registry (38%) and issues related to handling of missing data (32%). In addition, 25% of the respondents commented that biases might have compromised the validity of the results. More than 80% of the respondents reported that the registry improved the knowledge on the natural history and manifestations of TSC, increased disease awareness and helped to identify relevant information for clinical research in TSC.Conclusions: This analysis shows the importance of registries as a powerful tool to increase disease awareness, to produce real-world evidence, and to generate questions for future research. However, there is a need to implement strategies to ensure patient retention and long-term sustainability of patient registries, to improve data quality, and to reduce biases.
topic lessons
issues
strengths
weaknesses
TOSCA
registry
url https://www.frontiersin.org/article/10.3389/fneur.2019.01182/full
work_keys_str_mv AT rubenmarques thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT rubenmarques thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT elenabelousova thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT mirjanapbenedik thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT tomcarter thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT vincentcottin thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT paolocuratolo thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT mariadahlin thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT lisadamato thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT guillaumebeauredaugeres thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT petrusjdevries thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT josecferreira thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT marthafeucht thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT carlafladrowski thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT carlafladrowski thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT christophhertzberg thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT annacjansen thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT sergiuszjozwiak thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT sergiuszjozwiak thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT johnckingswood thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT johnalawson thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT alfonsmacaya thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT finbarocallaghan thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT jiongqin thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT valentinsander thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT matthiassauter thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT seemashah thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT yukitoshitakahashi thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT renaudtouraine thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT sotirisyouroukos thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT bernardzonnenberg thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT rimanabbout thetoscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT rubenmarques toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT rubenmarques toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT elenabelousova toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT mirjanapbenedik toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT tomcarter toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT vincentcottin toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT paolocuratolo toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT mariadahlin toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT lisadamato toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT guillaumebeauredaugeres toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT petrusjdevries toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT josecferreira toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT marthafeucht toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT carlafladrowski toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT carlafladrowski toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT christophhertzberg toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT annacjansen toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT sergiuszjozwiak toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT sergiuszjozwiak toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT johnckingswood toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT johnalawson toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT alfonsmacaya toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT finbarocallaghan toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT jiongqin toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT valentinsander toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT matthiassauter toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT seemashah toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT yukitoshitakahashi toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT renaudtouraine toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT sotirisyouroukos toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT bernardzonnenberg toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
AT rimanabbout toscaregistryfortuberoussclerosislessonslearntforfutureregistrydevelopmentinrareandcomplexdiseases
_version_ 1725154907155070976
spelling doaj-acb3460301534cc9a945482e7e3a42212020-11-25T01:15:00ZengFrontiers Media S.A.Frontiers in Neurology1664-22952019-11-011010.3389/fneur.2019.01182492865The TOSCA Registry for Tuberous Sclerosis—Lessons Learnt for Future Registry Development in Rare and Complex DiseasesRuben Marques0Ruben Marques1Elena Belousova2Mirjana P. Benedik3Tom Carter4Vincent Cottin5Paolo Curatolo6Maria Dahlin7Lisa D'Amato8Guillaume Beaure d'Augères9Petrus J. de Vries10José C. Ferreira11Martha Feucht12Carla Fladrowski13Carla Fladrowski14Christoph Hertzberg15Anna C. Jansen16Sergiusz Jozwiak17Sergiusz Jozwiak18John C. Kingswood19John A. Lawson20Alfons Macaya21Finbar O'Callaghan22Jiong Qin23Valentin Sander24Matthias Sauter25Seema Shah26Yukitoshi Takahashi27Renaud Touraine28Sotiris Youroukos29Bernard Zonnenberg30Rima Nabbout31Novartis Farma S.p.A., Origgio, ItalyInstitute of Biomedicine (IBIOMED), University of Leon, León, SpainResearch and Clinical Institute of Pediatrics, Pirogov Russian National Research Medical University, Moscow, RussiaSPS Pediatrična Klinika, Ljubljana, SloveniaTuberous Sclerosis Association, Nottingham, United KingdomHôpital Louis Pradel, Claude Bernard University Lyon 1, Lyon, FranceTor Vergata University Hospital, Rome, ItalyKarolinska University Hospital, Stockholm, SwedenNovartis Farma S.p.A., Origgio, ItalyAssociation Sclérose Tubéreuse de Bourneville, Gradignan, France0Division of Child and Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa1Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal2Universitätsklinik für Kinder-und Jugendheilkunde, Vienna, Austria3Associazione Sclerosi Tuberosa ONLUS, Milan, Italy4European Tuberous Sclerosis Complex Association, In den Birken, Datteln, Germany5Vivantes-Klinikum Neukölln, Berlin, Germany6Pediatric Neurology Unit, Department of Pediatrics, UZ Brussel VUB, Brussels, Belgium7Department of Child Neurology, Warsaw Medical University, Warsaw, Poland8Department of Neurology and Epileptology, The Children's Memorial Health Institute, Warsaw, Poland9Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Centre, St Georges University of London, London, United Kingdom0The Tuberous Sclerosis Multidisciplinary Management Clinic, Sydney Children's Hospital, Randwick, NSW, Australia1Hospital Universitari Vall d'Hebron, Barcelona, Spain2Institute of Child Health, University College London, London, United Kingdom3Department of Pediatrics, Peking University People's Hospital, Beijing, China4Tallinn Children Hospital, Tallinn, Estonia5Klinikverbund Kempten-Oberallgäu gGmbH, Kempten, Germany6Novartis Healthcare Pvt. Ltd., Hyderabad, India7National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO, Shizuoka, Japan8Department of Genetics, CHU-Hôpital Nord, Saint Etienne, France9St. Sophia Children's Hospital, Athens, Greece0University Medical Center, Utrecht, Netherlands1Department of Pediatric Neurology, Necker Enfants Malades Hospital, Imagine Institute, Inserm U1163, Paris Descartes University, Paris, FranceIntroduction: The TuberOus SClerosis registry to increase disease Awareness (TOSCA) is an international disease registry designed to provide insights into the clinical characteristics of patients with Tuberous Sclerosis Complex (TSC). The aims of this study were to identify issues that arose during the design, execution, and publication phases of TOSCA, and to reflect on lessons learnt that may guide future registries in rare and complex diseases.Methods: A questionnaire was designed to identify the strengths, weaknesses, and issues that arose at any stage of development and implementation of the TOSCA registry. The questionnaire contained 225 questions distributed in 7 sections (identification of issues during registry planning, during the operation of the registry, during data analysis, during the publication of the results, other issues, assessment of lessons learnt, and additional comments), and was sent by e-mail to 511 people involved in the registry, including 28 members of the Scientific Advisory Board (SAB), 162 principal investigators (PIs), and 321 employees of the sponsor belonging to the medical department or that were clinical research associate (CRA). Questionnaires received within the 2 months from the initial mailing were included in the analysis.Results: A total of 53 (10.4%) questionnaires were received (64.3% for SAB members, 12.3% for PIs and 4.7% for employees of the sponsor), and the overall completeness rate for closed questions was 87.6%. The most common issues identified were the limited duration of the registry (38%) and issues related to handling of missing data (32%). In addition, 25% of the respondents commented that biases might have compromised the validity of the results. More than 80% of the respondents reported that the registry improved the knowledge on the natural history and manifestations of TSC, increased disease awareness and helped to identify relevant information for clinical research in TSC.Conclusions: This analysis shows the importance of registries as a powerful tool to increase disease awareness, to produce real-world evidence, and to generate questions for future research. However, there is a need to implement strategies to ensure patient retention and long-term sustainability of patient registries, to improve data quality, and to reduce biases.https://www.frontiersin.org/article/10.3389/fneur.2019.01182/fulllessonsissuesstrengthsweaknessesTOSCAregistry